Drugs & Targets FDA grants Ambrx Fast Track designation for prostate cancer ADC therapy July 21, 2023Vol.49 No.29
Can ctDNA be used as an endpoint for cancer drug development?Friends collaboration to present initial results July 11 July 07, 2023Vol.49 No.27By Matthew Bin Han Ong
Drugs & Targets FDA establishes Oncology Quality, Characterization and Assessment of Real-World Data Initiative June 30, 2023Vol.49 No.26
In the era of immunotherapy and targeted therapies, ODAC focuses on dose optimization in children June 23, 2023Vol.49 No.25By Jacquelyn Cobb
Drugs & Targets FDA approves Talzenna with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer June 23, 2023Vol.49 No.25
An oncologist’s nightmare: “As of today, we no longer have any supply of carboplatin.” June 16, 2023Vol.49 No.24By Paul Goldberg
Drugs & Targets FDA grants priority review to capivasertib + Faslodex for advanced HR-positive breast cancer June 16, 2023Vol.49 No.24
Drugs & Targets FDA approves Lynparza with abiraterone, prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer June 02, 2023Vol.49 No.22
Drugs & Targets FDA approves Posluma—first radiohybrid PSMA-targeted PET imaging agent for prostate cancer June 02, 2023Vol.49 No.22
Drugs & Targets FDA grants priority review to repotrectinib for locally advanced or metastatic ROS1-positive NSCLC June 02, 2023Vol.49 No.22
